Dennis A. Hanson
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dennis A. Hanson.
Journal of Immunology | 2000
William Ernst; Sybille Thoma-Uszynski; Rachel Teitelbaum; C. Ko; Dennis A. Hanson; Carol Clayberger; Alan M. Krensky; Matthias Leippe; Barry R. Bloom; Tomas Ganz; Robert L. Modlin
Granulysin, a protein located in the acidic granules of human NK cells and cytotoxic T cells, has antimicrobial activity against a broad spectrum of microbial pathogens. A predicted model generated from the nuclear magnetic resonance structure of a related protein, NK lysin, suggested that granulysin contains a four α helical bundle motif, with the α helices enriched for positively charged amino acids, including arginine and lysine residues. Denaturation of the polypeptide reduced the α helical content from 49 to 18% resulted in complete inhibition of antimicrobial activity. Chemical modification of the arginine, but not the lysine, residues also blocked the antimicrobial activity and interfered with the ability of granulysin to adhere to Escherichia coli and Mycobacterium tuberculosis. Granulysin increased the permeability of bacterial membranes, as judged by its ability to allow access of cytosolic β-galactosidase to its impermeant substrate. By electron microscopy, granulysin triggered fluid accumulation in the periplasm of M. tuberculosis, consistent with osmotic perturbation. These data suggest that the ability of granulysin to kill microbial pathogens is dependent on direct interaction with the microbial cell wall and/or membrane, leading to increased permeability and lysis.
Journal of Immunology | 2001
Allan A. Kaspar; Satoshi Okada; Jayant Kumar; Francis R. Poulain; Katerina A. Drouvalakis; Ameeta Kelekar; Dennis A. Hanson; Ruth M. Kluck; Yasumichi Hitoshi; Daniel E. Johnson; Christopher J. Froelich; Craig B. Thompson; Donald D. Newmeyer; Alberto Anel; Carol Clayberger; Alan M. Krensky
Granulysin is an antimicrobial and tumoricidal molecule expressed in granules of CTL and NK cells. In this study, we show that granulysin damages cell membranes based upon negative charge, disrupts the transmembrane potential (Δψ) in mitochondria, and causes release of cytochrome c. Granulysin-induced apoptosis is blocked in cells overexpressing Bcl-2. Despite the release of cytochrome c, procaspase 9 is not processed. Nevertheless, activation of caspase 3 is observed in granulysin-treated cells, suggesting that granulysin activates a novel pathway of CTL- and NK cell-mediated death distinct from granzyme- and death receptor-induced apoptosis.
Journal of Immunology | 2000
Zhuo Wang; Edward Choice; Allan A. Kaspar; Dennis A. Hanson; Satoshi Okada; Shu Chen Lyu; Alan M. Krensky; Carol Clayberger
Granulysin, a 9-kDa protein localized to human CTL and NK cell granules, is cytolytic against tumor cells and microbes. Molecular modeling predicts that granulysin is composed of five α-helices separated by short loop regions. In this report, synthetic peptides corresponding to the linear granulysin sequence were characterized for lytic activity. Peptides corresponding to the central region of granulysin lyse bacteria, human cells, and synthetic liposomes, while peptides corresponding to the amino or carboxyl regions are not lytic. Peptides corresponding to either helix 2 or helix 3 lyse bacteria, while lysis of human cells and liposomes is dependent on the helix 3 sequence. Peptides in which positively charged arginine residues are substituted with neutral glutamine exhibit reduced lysis of all three targets. While reduction of recombinant 9-kDa granulysin increases lysis of Jurkat cells, reduction of cysteine-containing granulysin peptides decreases lysis of Jurkat cells. In contrast, lysis of bacteria by recombinant granulysin or by cysteine-containing granulysin peptides is unaffected by reducing conditions. Jurkat cells transfected with either CrmA or Bcl-2 are protected from lysis by recombinant granulysin or the peptides. Differential activity of granulysin peptides against tumor cells and bacteria may be exploited to develop specific antibiotics without toxicity for mammalian cells.
Molecular Immunology | 1999
Dennis A. Hanson; Allan A. Kaspar; Francis R. Poulain; Alan M. Krensky
Granulysin is a newly described lytic molecule expressed by CTL and NK cells. Three mRNA (519, 520, and 522) and two protein products of 15 and 9 kDa are encoded by the granulysin gene. Stable transfectants overexpressing the predominate 520 mRNA were generated to determine the protein products originating from the translation of this message. A transfectant of the NK cell tumor YT overexpressed both 15 and 9 kDa proteins while a transfectant of the T cell tumor HuT78 produced mainly 15 kDa granulysin. Thus the 520 mRNA is sufficient for production of both 15 and 9 kDa granulysin. 9 kDa granulysin accumulated via post-translational processing of 15 kDa protein and was present intracellularly but not in the cell culture supernatant, indicating specific retention of the 9 kDa protein. An inhibitor of granule acidification, concanamycin A, blocked the processing of 15 kDa granulysin to the 9 kDa form. A deduced structural difference between the two forms of the protein and a decrease in lytic activity of 9 kDa granulysin at granule pH suggest two mechanisms by which a granulysin expressing cell is protected from autolysis during the biosynthesis of this potentially harmful molecule.
Molecular Immunology | 2002
Dennis A. Hanson; Steven F. Ziegler
Cross-linking the high affinity IgE receptor on the rat basophil leukemia clone 2H3 (RBL-2H3) cell line, an vitro model for mast cell signaling, results in granule release. A great deal of research has focused on the earliest steps in this signaling cascade resulting in models which include the participation of lyn, syk, phospholipase C (PLC), protein kinase C (PKC) and intracellular calcium mobilization. In an effort to look at pathways downstream of calcium mobilization, ionomycin-mediated granule release was studied. The kinase inhibitors PP1 (src family), GF109203X (PKC), PD98059 (MEK1/2), and U0126 (MEK1/2) substantially inhibited ionomycin-mediated granule release, while the p38 kinase inhibitor SB203580 did not. Both p38 and erk were phosphorylated upon ionomycin treatment, but only extracellular regulated kinase (erk) activation was completely inhibited by PP1 treatment and partially inhibited by the MEK inhibitors, thus, correlating with the granule release data. Interestingly, while GF109203X alone had no affect on erk activation, combining it with U0126 completely blocked this response. This suggests the existence an alternate pathway for erk activation that is MEK independent and PKC dependent. Experiments in which ionomycin and PP1 were titrated (independently) demonstrated a correlation between erk phosphorylation and granule release, implicating erk in a PP1-inhibitable pathway operating downstream of calcium and controlling mast cell degranulation.
Science | 1998
Steffen Stenger; Dennis A. Hanson; Rachel Teitelbaum; Puneet Dewan; Kayvan Niazi; Christopher J. Froelich; Tomas Ganz; Sybille Thoma-Uszynski; Agustín Melián; Christian Bogdan; Steven A. Porcelli; Barry R. Bloom; Alan M. Krensky; Robert L. Modlin
Journal of Experimental Medicine | 2000
Franca M. Spada; Ethan P. Grant; Peter J. Peters; Masahiko Sugita; Augustín Melián; David S. Leslie; Hoi K. Lee; Elly van Donselaar; Dennis A. Hanson; Alan M. Krensky; Otto Majdic; Steven A. Porcelli; Craig T. Morita; Michael B. Brenner
Journal of Immunology | 1997
Susan V. Peña; Dennis A. Hanson; Brian A. Carr; Thomas J. Goralski; Alan M. Krensky
Journal of Experimental Medicine | 2000
Spada Fm; Ethan P. Grant; Peter J. Peters; Masahiko Sugita; Augustín Melián; David S. Leslie; Lee Hk; van Donselaar E; Dennis A. Hanson; Alan M. Krensky; Majdic O; Steven A. Porcelli; Craig T. Morita; Michael B. Brenner
Journal of Immunology | 1998
Susana Gamen; Dennis A. Hanson; Allan A. Kaspar; Javier Naval; Alan M. Krensky; Alberto Anel